Latest Us Manufacturing News

Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.

Environmental Clean Technologies says its proposed Xenica acquisition has gained a defence-market sublicence for MXenes, adding a potential route to customers for its Flash Joule Heating platform. The agreement is not a customer contract, and revenue still depends on acquisition completion, repeatable production and qualification.

Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.

Boresight Ltd’s US subsidiary has landed a US$383,275 purchase order from a repeat North American military customer, tripling previous drone orders and expanding its footprint in counter-drone training.

Iondrive Limited’s updated evaluation of its IONSolv™ technology projects a US$243 million post-tax NPV and US$62 million annual EBITDA for a single rare earth recovery module in the US, driven by high feedstock grade assumptions and independently validated recoveries.

AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.

Yowie Group's revenue declined in the first half of 2026 as it navigated supply chain shifts and cautious retail demand, but the company secured a significant Australian licensing deal and ended costly legacy litigation.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

IperionX plans to relocate its parent company to Texas and list directly on Nasdaq, aligning its corporate structure with its US operations. The appointment of manufacturing veteran Michael J. Loparco aims to bolster the company’s industrial scale-up.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Boresight Ltd (ASX: BST) marked its ASX debut in June with a successful $8 million IPO, reporting a 55% revenue increase in FY26 and securing a major US manufacturing expansion to meet rising defence drone demand.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.